The short answer
IGF-1 and its analogues appear on the WADA Prohibited List under class S2, peptide hormones, growth factors, related substances and mimetics,prohibited at all times, both in and out of competition.
Key facts
- WADA class
- S2
- Class covers
- Peptide hormones, growth factors, mimetics
- Prohibited
- At all times (in and out of competition)
- Covers analogues
- Yes (engineered forms included)
- Also in S2
- Growth hormone and its secretagogues
- Marketing authorisation
- None for LR3
What class S2 is
Peptide hormones, growth factors, related substances and mimetics. It covers growth hormone, its releasing factors and secretagogues, erythropoietin and related agents, and the IGF-1 family. These are substances that act on endogenous signalling systems, which is what groups them.
What prohibited at all times means
Some substances are prohibited only in competition, on the reasoning that their effect is acute. S2 substances are prohibited in and out of competition, because their effects develop over time and out-of-competition use would otherwise carry the benefit into competition. Testing applies year-round.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
Why analogues are covered explicitly
The list names substances and then extends to related substances and mimetics, so that a structural modification does not create an exemption. An engineered IGF-1 analogue with an N-terminal extension and a substitution is squarely within that scope. The modification is the reason the wording exists.
The separate regulatory position
Anti-doping and medicines regulation are different frameworks. IGF-1 LR3 holds no marketing authorisation from any regulator, which is a separate fact from its prohibited status. A compound can be prohibited in sport and licensed as a medicine (mecasermin is) or, as here, prohibited and unlicensed both.
Why this site states it clearly
Because anyone competing under an anti-doping code needs the information without having to infer it. Material supplied here is for laboratory research only, and nothing about the research context alters what the Prohibited List covers.
Frequently asked questions
Is IGF-1 LR3 banned in sport?
Yes. IGF-1 and its analogues are in WADA class S2, prohibited at all times in and out of competition.
Does modifying the molecule avoid the classification?
No. The list extends to related substances and mimetics specifically so that structural modification creates no exemption.
Is prohibited status the same as being unlicensed?
No, they are separate frameworks. LR3 happens to be both prohibited in sport and unlicensed as a medicine.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- IGF-1 LR3 Regulatory StatusNo marketing authorisation anywhere, though an approved native rhIGF-1 exists. Why that distinction is the important one in this category.
- A Natural Experiment in Absent IGF-1People with growth hormone receptor deficiency produce almost no IGF-1. Laron and Werner report that they do not develop cancer.
- A Strong Rationale That Did Not TranslateThe IGF-1 receptor was pursued as an oncology target on excellent biological grounds. The clinical programmes largely failed, and why is instructive.
- A Regulatory System, Deliberately EvadedIGF binding proteins restrain IGF-1 availability. LR3 exists to escape them. Set against the Laron findings, that is worth stating plainly.
- Two Hormones, One Feedback LoopGrowth hormone acts on the liver, the liver produces IGF-1, and IGF-1 feeds back to suppress growth hormone. Laron syndrome breaks the loop mid-way.